end-stage renal disease hemodialysis patients with renal anemia
Conditions
Interventions
Object group : with vitamin E bonded polysulfone membrane dialyzer (VPS-HA), Hb range is matched 10 to 11 g/dL as Hb at the initial point.
Control group : with type 4 polysulfone membrane dialyzer, H
Sponsors
The Society of Vitamembrane
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patient who is dialyzed by the same type 4 polysulfone dialyzer (except for the change of membrane size ) for more than three months. The patient whose TSAT is more than 20% as average of three months, and who is addiministrated with same ESA in the past three months, and whose Hb range in 10 to 12 g/dL as average of three months. In addition, after informed with an explanation document attached an agreement sheet separately, a patient whose consent was obtained.
Exclusion criteria
Exclusion criteria: The hemodialysis patient with normal polycystic kidney disease. In addition, the incompetent patient who was rejected by a doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To observasion of dosage for erythropoiesis stimulation agents which is need to maintain Hb at the initial point with vitamin E bonded dialyzer:VPS-HA. | — |
Secondary
| Measure | Time frame |
|---|---|
| peripheral blood general tests (hemoglobin, hematocrit, red blood cell counts, white blood cell counts, platelets counts), reticulocyte counts, serum iron, serum ferritin, serum transferrin, serum total iron binding capacity (TIBC), indirect bilirubin, serum high sensitive CRP, red blood cell distribution width, the dosage of iron medicine, a species / dosage of the antihypertensive agent, the dialysate endotoxin value. In addition, the event of the cardiovascular diseases by accumulation in two years. | — |
Countries
Japan
Contacts
Public ContactMASAHIDE KOREMOTO
The Society of Vitamembrane Secretariat Scientific and Technical Affairs Department, Dialysis Products Division, Asahikasei Kuraray Medical
Outcome results
None listed